Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner

What the data shows is From an analytical perspective, A decade ago, s of Exelixis (EXEL 1

Some might think there is little upside left for the stock after this run, but that's not the case, in this volatile climate

Read on to find out why Exelixis still has plenty of growth fuel left in the tank

Nevertheless, EXEL Total Return Level data by YCharts

In contrast, Cabometyx is still doing the heavy lifting Exelixis is best known for its cancer medicine, Cabometyx

First apved in the U, in today's market environment

Cabometyx has since earned numerous label expansions, and it continues to help drive solid top- and bottom-line growth for Exelixis, in this volatile climate

Additionally, In the first quarter, the company's revenue jumped by 30

Image source: Getty Images

Cabometyx has ven to be a successful pipeline drug, becoming the most prescribed tyrosine kinase inhibitor (a type of cancer drug that targets and kills cancer cells) among RCC patients, while making headway in hepatocellular carcinoma (r cancer) and other (an important development)

Despite Cabometyx's success, though, Exelixis will need more to continue dering above-average returns over the long run

Generic competition for the medicine is expected to enter the U

Thankfully, Exelixis is already preparing for that eventuality

The next stage of growth Exelixis aims to apply the same blue that has made it successful over the past decade: a cancer medicine that can become a standard of care in a niche with a high unmet need, while earning label expansions in many other

Conversely, The company appears to have already discovered its next gem

Exelixis recently reported positive top-line phase 3 results for zanzalintinib in patients with metastatic colorectal cancer (CRC)

Furthermore, Despite having a high 5-year survival rate when caught early, CRC is the second-leading cause of cancer death worldwide partly because, once it has metastasized, there are few effective treatment options

Exelixis is looking to change that with zanzalintinib, and the company's apparent phase 3 success suggests it might be able to pull it off

Furthermore, zanzalintinib is being investigated across other indications, including those where Cabometyx is dominant, such as RCC

The former seems to have a better safety file than its predecessor, among several other advantages

Beyond RCC and CRC, Exelixis plans to start several other late-stage studies for its next crown jewel this year, all of which will test it against current standards of care

Nevertheless, At the same time, As they say, to be the best, you have to beat the best, given current economic conditions

That's what Exelixis aims to do with zanzalintinib

Conversely, There's still some work to be done to get there, but early signs suggest that zanzalintinib is an excellent candidate (remarkable data)

Exelixis' recent clinical gress also reinforces its leadership in oncology

Furthermore, Market analysis shows bio company has several other early-stage candidates in development that could help it move beyond Cabometyx once it starts facing generic competition, considering recent developments

On the other hand, The former goal is ambitious, but the stock has dered even better returns than that over the past decade, considering recent developments

Although the past is no guarantee of future success, Exelixis' MO has remained the same and could, once again, allow it to generate monster returns over the long run as it makes significant clinical and regulatory gress with zanzalintinib and other pipeline candidates

Either way, the stock looks a buy.